38 results about "Cachexia" patented technology

The invention relates to an application of an amide substituted 2-oxopyridine compound. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, an optically pure isomer, a stereoisomer or a mixture thereof, is used for preparing a medicine or a preparation, and the medicine or the preparation is used for one or more of the following applications: (a) a medicine for treating and / or preventing cachexia-related diseases, (b) a medicine for treating and / or preventing cachexia-related diseases, (c) a medicine for treating and / or preventing cachexia-related diseases, and (c) a medicine for treating and / or preventing cachexia-related diseases; (b) inhibiting the browning of fat cells; and / or (c) promoting the degradation of the PRDM16 protein; wherein the compound shown in the formula (I) has a structure shown in the specification,

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The invention discloses a marker for combined diagnosis of pancreatic cancer cachexia. The research finds that the serum pancreatic cancer exosome miR-203a-3p can be used for diagnosing pancreatic cancer cachexia or early stage of pancreatic cancer cachexia independently or in combination with nutrition inflammation indexes, and has relatively high diagnosis efficiency, and the diagnosis efficiency is greatly improved after the miR-203a-3p is combined with other indexes; a new direction is provided for effective diagnosis and treatment of pancreatic cancer cachexia or precachexia of pancreatic cancer, and the application prospect is wide.

The present application relates to a kind of water gel based on crude polysaccharide of Radix Trichosanthis and its preparation method and application.The water gel based on crude polysaccharide of Radix Trichosanthis is prepared by the following method:1) preparing crude polysaccharide of Radix Trichosanthis;2) making aldehyde group of crude polysaccharide of Radix Trichosanthis to obtain aldehyde group of crude polysaccharide of Radix Trichosanthis;And 3) aldehyde group of crude polysaccharide of Radix Trichosanthis and carboxymethyl cellulose are covalently combined to form the water gel by Schiff base reaction.The multifunctional water gel of the present application is expected to become the candidate dressing of clinical protection and treatment of cachexia wound and other immunosuppressive chronic wound.

The application provides application of ABT199 in preparation of a drug for treating muscle atrophy. Compared with the prior art, the application provides a new use of ABT199 in treating muscle atrophy. Experimental research proves that ABT199 administration can significantly restore the exercise capacity of a cachexia-induced muscle atrophy mouse, improve the muscle cross-sectional area of the mouse, restore the reduced glutathione content of the mouse, and improve the superoxide dismutase activity, so as to improve the muscle atrophy phenotype of the mouse and muscle atrophy-related biochemical indexes. ABT199 can significantly restore cell muscle atrophy-related gene and protein expression, and improve the cachexia-induced muscle atrophy phenotype by reducing related inflammatory mediators; ABT199 can significantly improve the mitochondrial membrane potential, increase the expression of mitochondrial neogenesis-related genes, and reduce the production of active oxygen.

To provide a new compound useful for treating cachexia or wasting syndrome which is a severe complication of chronic diseases such as neurodegenerative diseases and cancer.SOLUTION: Compounds of formula Ib or Ic are described. The compounds can modify the Akt3 or effects of nature in vitro or in vivo, and can also be used, alone or in combination with other agents, in the prevention or treatment of various conditions.SELECTED DRAWING: Figure 1

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for replenishing qi, enriching blood, tonifying spleen and nourishing kidney as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 to 12 parts of radix angelicae sinensis, 5 to 20 parts of radix codonopsis, 5 to 20 parts of radix astragali seu hedysari, 2 to 12 parts of rhizoma atractylodis macrocephalae, 2 to 15 parts of poria cocos, 3 to 13 parts of colla corii asini, 3 to 13 parts of tortoise-shell glue, 2 to 12 parts of herba cistanche, 5 to 15 parts of radix rehmanniae praeparata, 3 to 15 parts of rhizoma polygonati, 3 to 13 parts of herba epimedii, 2 to 12 parts of fructus crataegi, 5 to 15 parts of arillus longan, 2 to 12 parts of fructus ligustri lucidi, 2 to 6 parts of fructus schisandrae chinensis and 1 to 5 parts of cortex cinnamomi. The traditional Chinese medicine composition has the main effects of replenishing qi, enriching blood, tonifying spleen and nourishing kidney, is used for rehabilitation after cancer surgery or chemotherapy and used for resisting cancer relapse, is particularly used for patients with spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy, and improves the problems of emaciation, insomnia, inappetence, mental fatigue and tiredness and the like of the patients with the patients with the spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy.

The present invention provides a GDF15-binding nanoantibody, and a use thereof in preparation of a drug for treating tumor cachexia and in detection of GDF15. The nanoantibody provided in the present invention exhibits high affinity for GDF-15 and is capable of blocking the binding of GDF-15 to GFRAL.

To provide safe and effective compositions and methods for enhancing the efficacy and / or reducing the side effects of cancer chemotherapy and increasing the sensitivity of chemotherapy-resistant cancer cells.SOLUTION: Nutritional supplements comprising fish oil and selenium have been found to provide various activities that are beneficial in treating cancer and related conditions. The supplement provides a synergistic effect in reducing cancer cell growth when used in combination with a chemotherapeutic agent and can reduce growth in drug resistant cancer cells when used in combination with a chemotherapeutic agent to which the cells are resistant. Effects in reducing angiogenesis, reducing metastasis, decreasing the number of circulating cancer cells, and altering AXL signaling have also been found. The use of the supplement was found to reduce the wasting associated with cachexia and decrease circulating cytokines associated with inflammation. The overall effect was found to prolong survival in a clinical study.SELECTED DRAWING: Figure 1

The invention discloses an application of a compound or a pharmaceutical salt thereof in preparation of a medicine for preventing or treating tumor cachexia diseases. The structure of the compound is shown in the specification. The result of the embodiment of the invention shows that the compound provided by the invention can inhibit skeletal muscle atrophy so as to treat or improve tumor cachexia.

The present application relates to a composition for preventing, improving or treating cachexia or anticancer chemotherapy side effects, containing Lactobacillus reuteri ATG-F4 strain as an effective ingredient.

This invention proposes an antibody or antigen-binding fragment thereof that binds to GDF15. The antibody or antigen-binding fragment comprises: a CDR sequence selected from at least one of the following or an amino acid sequence having at least 66% identity with it: heavy chain variable region CDR sequence: SEQ ID NO: 1-34 and SEQ ID NO: 74-76; light chain variable region CDR sequence: SEQ ID NO: 36-73 and SEQ ID NO: 77-82. According to embodiments of the invention, the antibody or antigen-binding fragment thereof can specifically bind to GDF15 and effectively block the binding of GFRAL and GDF15, while also effectively inhibiting Treg differentiation, and can be used for the prevention and / or treatment of cancer and cachexia.

Disclosed are methods and compositions related to treatment, amelioration or prevention of cachexia or inflammation related to cachexia in a subject. As disclosed, cachexia or inflammation related to cachexia can be treated, ameliorated or prevented by the administration of an effective amount of a composition including immune-modulating fibroblasts to the subject.

This invention discloses GDF15 micro-binding agents and their applications. This application provides a novel class of micro-binding agents specifically targeting the GDF15-GFRAL signaling pathway. These micro-binding agents possess extremely high binding affinity, excellent structural stability, and good in vitro and in vivo functional activity. Experiments show that these micro-binding agents can significantly reverse cancer-related cachexia in various tumor models, restore body weight, and prolong survival; simultaneously, they can restore sensitivity to PD-1 immune checkpoint inhibitors and enhance CD8... + The infiltration and function of T cells in the tumor microenvironment have broad clinical application prospects.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.

The present invention provides a method of treating or ameliorating cachexia. The invention provides an application of NUCBs (nucleonectin, NUCBs), which is characterized in that the NUCBs can be used for preparing the NUCBs. By means of the method, (a) weight loss and (b) body fat reduction caused by cachexia can be well improved or treated, and the life quality of patients with cachexia is improved.

The invention discloses a traditional Chinese medicine composition for treating non-small cell lung cancer, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating the non-small cell lung cancer comprises the following raw materials in parts by weight: 1-10 parts of chamomile, 1-10 parts of dandelion and 1-10 parts of rhizoma smilacis glabrae. The traditional Chinese medicine composition-chamomile compound has an obvious inhibition effect on lung adenocarcinoma, and can obviously inhibit tumor cell growth and induce tumor cells to die after being taken; the pathological state of lung cancer tissues is improved, and tumor-related cachexia is effectively relieved; the appetite is improved, and progressive weight loss caused by tumors is prevented.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating tumor cachexia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-15 parts of cassia twigs, 16-24 parts of radix paeoniae alba, 13-21 parts of fresh ginger, 7-15 parts of Chinese dates and 4-12 parts of liquorice. The traditional Chinese medicine composition is a full traditional Chinese medicine formula, has the advantages of easily available medicine sources, obvious drug effect, few side effects and simple preparation process, can effectively improve the processes of weight loss, fat loss and muscle atrophy of tumor cachexia patients, improves the treatment effect and the life quality, prolongs the survival time of the patients, and can be used for preparing drugs for treating tumor cachexia.

The present invention relates to a composition for preventing, alleviating or treating sarcopenia, comprising a Plantago asiatica extract as an active ingredient. The Plantago asiatica extract of the present invention has no C2C12 cytotoxicity, has an effect in alleviating muscle loss in a cell experimental model through inhibition of muscle cell differentiation, and has an effect on muscle loss by alleviating skeletal muscle loss in a cachexia-induced muscle loss animal model.

The invention discloses an intelligent high-precision weighing device for dietary therapy food materials of a diabetic with emaciation. The intelligent high-precision weighing device is used for measuring the obesity degree. Calculating daily total energy; heat energy occupied by the three nutrients is calculated, and the heat energy occupied by the three nutrients is calculated according to the heat generation ratio of the three heat generation nutrients in the daily diet of normal adults recommended by the Chinese Nutrition Society; respectively calculating the daily required amounts of the three major nutrients; adjusting the structure and quantity of the whole nutrients; in the first step, the staple food amount is determined; and then each auxiliary food intake is determined. The device can accurately and ingeniously avoid diet taboo, accurately formulate personalized recipes for marsh diabetic patients, open a kitchen diet therapy way of high-precision standardized food material weighing, flexibly adjust food material contents and increase food diversification, so that the compliance of the patients can be greatly improved, and the dietary therapy effect of the patients is improved. The success rate of blood sugar control is greatly increased for a user, the effectiveness of blood sugar stability is maintained, and complications of a patient are prevented after long-term use.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule from the pro-opiomelanocortin (POMC) gene encoding the β-MSH peptide. Preferably, the RNA editing changes a tyrosine to a cysteine at position 221 (Y221C) in the POMC prohormone, which results in a loss-of-function of the encoded β-MSH peptide. In turn, treatment using the AONs as disclosed will result in gain of body weight and increased BMI, thereby lowering the risk of suffering from weight loss related metabolic disorders such as cachexia.

The invention relates to a medicine for preventing or treating skeletal muscle atrophy of mammals. The medicine comprises an active component from a medicine pair of frankincense-myrrh, and the active component is selected from any one or a combination of more of masticinic acid AKBA, alpha-pinene and guggulsterone. The invention reveals that the active ingredients can remarkably improve skeletal muscle atrophy induced by various pathological factors such as cachexia, glucocorticoid or inflammatory factors for the first time, and a clear basis is provided for development of anti-skeletal muscle atrophy drugs based on traditional Chinese medicine active ingredients.

The invention discloses an application of bile acid in preparation of a medicine for treating tumor cachexia. The invention proposes and verifies that deoxycholic acid in bile acid, especially secondary bile acid, can effectively recover the weight of a tumor cachexia model mouse for the first time, and inhibits the level of fat degradation related protein, increases the lipid droplet size of fat cells, improves the weight and cross-sectional area of fat tissues, and improves the tumor cachexia model mouse weight. The invention provides a therapeutic drug with great application potential for weight loss and adipose tissue depletion symptoms caused by tumor cachexia.

A method of treatment and use of probiotic compositions in treatment of weight loss-related conditions in wasting, and cachexia, includes the steps of administering a probiotic composition to a subject deemed in need of such treatment wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp, and a probiotic composition for use in treatment of a subject having a weight loss-related condition wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a medicine preparation containing icariin in tumor cachexia. The medicine preparation containing icariin comprises first icariin-containing granules, second icariin-containing granules and additional molding accessories. The first icariin-containing granules comprise icariin, a solid dispersion carrier, a lipid solubilization component and a surface active component. The second icariin-containing granules further comprise an intestinal segment release adjusting accessory on the basis of the above components. The first icariin-containing granules and the second icariin-containing granules are combined in a predetermined mass ratio, and are prepared into tablets, capsules, granules or pills. The two types of icariin-containing granules form a release process in which the front release is connected with the rear release, simultaneously reduce the precipitation tendency of icariin in the release medium, improve the consistency of the distribution and release behavior of the active ingredients in the administration unit, and provide a stable preparation basis for oral intervention in tumor cachexia.

Provided herein are compositions comprising a non-naturally occurring melanocortin analogue in combination with a spiro compound and / or an antibody or antigen-binding fragment thereof. The composition may further include an anti-cancer agent (e.g., a chemotherapeutic agent). Also provided herein are pharmaceutical compositions incorporating the compositions; methods of using the compositions to modulate weight, including but not limited to increasing appetite, preventing inappetence, promoting weight gain, preventing weight loss, and / or treating, preventing, or otherwise reducing cachexia and / or anorexia in a subject in need thereof.

The application relates to application of a recombinant protein to preparation of a medicine for inhibiting muscle atrophy, and belongs to the field of biological medicines. The application discloses application of a recombinant protein AGGF1 to preparation of a medicine for inhibiting muscle atrophy. The recombinant AGGF1 protein can inhibit mouse muscle atrophy (peripheral nerve injury muscle atrophy and cachexia muscle atrophy) and loss of skeletal muscle cell protein content. Therefore, the recombinant AGGF1 protein can be used for preparation of an anti-muscle atrophy medicine and treatment of muscle atrophy caused by lumbar intervertebral disc herniation and cachexia.